PPARA and liver cancer: Chronictreatment with PPARα agonist results in an increased incidence of liver tumorswhich were thought to have occurred through a PPARα-mediated mechanism asrevealed by the resistance of PPARα-null mice to liver cancer induced byWy-14,643 exposure for 11 months [46].